Overview

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
0
Participant gender:
Female
Summary
This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The secondary objectives are to evaluate: 1. Clinical benefit rate (CBR) and Objective Response Rate (ORR) 2. Duration of response 3. Time to response 4. Overall Survival (OS) 5. Pharmacokinetics of lasofoxifene 6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar assessment scale (VuAS) questionnaires 7. Safety of lasofoxifene 8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N).
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sermonix Pharmaceuticals Inc.
Sermonix Pharmaceuticals LLC
Collaborator:
Linical Accelovance Group
Treatments:
Antineoplastic Agents
Estradiol
Estrogen Antagonists
Estrogen Receptor Antagonists
Fulvestrant
Criteria
Inclusion Criteria:

1. Pre- or postmenopausal.

Postmenopausal women are defined as:

1. ≥60 years of age with no vaginal bleeding over the prior year, or

2. <60 years with "premature menopause" or "premature ovarian failure" manifest
itself with secondary amenorrhea for at least 1 year and follicle stimulating
hormone (FSH) and estradiol levels in the postmenopausal range according to
institutional standards, or

3. surgical menopause with bilateral oophorectomy. Note: premenopausal women who
meet all of the other entry criteria must be maintained on ovarian suppression
(such as Lupron) during the study and subjects counseled to use appropriate
contraception to prevent pregnancy.

2. If possible, a biopsy of metastatic breast cancer tissue will be obtained to provide
histological or cytological confirmation of ER+ and HER2- disease as assessed by a
local laboratory, according to the American Society of Clinical Oncology/College of
American Pathologists (ASCO/CAP) guidelines, using slides, paraffin blocks, or
paraffin samples. If a biopsy is not possible, the ER and HER2 status from the tissue
obtained at the time of the original diagnosis must confirm that the subject's cancer
is ER+ and HER2-.

3. Locally advanced or metastatic breast cancer with radiological or clinical evidence of
progression on an AI in combination with a CDK 4/6 inhibitor for advanced breast
cancer with demonstrated prior sensitivity to endocrine therapy (recurrence or
progression after at least 12 months of treatment in the metastatic setting).

4. Locally advanced or metastatic breast cancer with either measurable (according to
RECIST 1.1) or non-measurable lesions.

5. At least one or more of the following point ESR1 mutations as assessed in cell-free
circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S,
Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The
ctDNA sample collection must be obtained within 30 days prior to randomization to
determine eligibility and baseline. Note: a prior genomic test confirming that the
subject has an ESR1 mutation can be used to determine eligibility; however, an ESR1
sample must also be collected within 30 days of randomization.

6. Subjects who have not received cytotoxic chemotherapy or those who have received one
cytotoxic chemotherapy regimen in the neo-adjuvant or adjuvant setting prior to entry
into the trial and/or no more than one chemotherapy regimen for metastatic breast
cancer. Subjects must be free of all chemotherapy acute toxicity excluding alopecia
and Grade II peripheral neuropathy before study entry.

7. ECOG performance score of 0 or 1.

8. Adequate organ function as shown by:

1. absolute neutrophil count (ANC) >/=1,500 cells/mm3

2. platelet count ≤100,000 cells/mm3

3. hemoglobin >/=9.0 g/dl

4. ALT and AST levels ≤2.5 upper limit of normal (ULN) or ≤5 in the presence of
visceral metastasis

5. total serum bilirubin ≤1.5 X ULN (≤ 3 X ULN for subjects known to have Gilbert
Syndrome)

6. alkaline phosphatase level ≤ 2.5 X ULN

7. creatinine clearance of 40 ml/min or greater as calculated by the Cockcroft-Gault
formula

8. International normalized ratio (INR), activated partial thromboplastin (aPTT), or
partial thromboplastin time (PTT) <2.0 X ULN.

9. Able to swallow tablets.

10. Able to understand and voluntarily sign a written informed consent before any
screening procedures.

Exclusion Criteria:

1. Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or
phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued
to reasons other than disease progression.

2. Presence of brain metastasis.

3. Lymphangitic carcinomatosis involving the lung.

4. Impending visceral crisis in need of cytotoxic chemotherapy as assessed by the
investigator.

5. Radiotherapy within 30 days prior to randomization except in case of localized
radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which
can then be completed within 7 days prior to randomization. Subjects must have
recovered from radiotherapy toxicities prior to randomization.

6. History of long QTC syndrome or a QTC of >480 ms.

7. History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6
months or any known thrombophilia. Subjects stable on anti-coagulants for maintenance
are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and
there is no evidence for active thrombosis. The use of low dose ASA is permitted.

8. Any significant co-morbidity that would impact the study or the subject's safety.

9. History of a positive human immunodeficiency virus (HIV), hepatitis B virus (HBV) or
hepatitis C virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load)
are eligible.

10. History of malignancy within the past 5 years (excluding breast cancer), except basal
cell or squamous cell carcinoma of the skin curatively treated by surgery, or early
stage cervical cancer.

11. History of vaginal bleeding over the last year unless it is documented that the
bleeding was due to non-uterine causes (e.g. vaginal atrophy).

12. Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg or diastolic
pressure >100 mm Hg at Screening.

13. History of non-compliance to medical regimens.

14. Unwilling or unable to comply with the protocol.

15. Current participation in any clinical research trial involving an investigational drug
or device within the last 30 days.